The stock price of Pyxis Oncology Inc (NASDAQ: PYXS) has dropped by -6.21 compared to previous close of 4.83. Despite this, the company has seen a fall of -14.04% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-12 that The average of price targets set by Wall Street analysts indicates a potential upside of 61.3% in Pyxis Oncology (PYXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is It Worth Investing in Pyxis Oncology Inc (NASDAQ: PYXS) Right Now?
The 36-month beta value for PYXS is also noteworthy at 1.39. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PYXS is 46.27M, and at present, short sellers hold a 5.84% of that float. The average trading volume of PYXS on April 19, 2024 was 916.07K shares.
PYXS’s Market Performance
PYXS stock saw a decrease of -14.04% in the past week, with a monthly decline of -12.04% and a quarterly a decrease of 108.28%. The volatility ratio for the week is 9.21%, and the volatility levels for the last 30 days are 12.87% for Pyxis Oncology Inc (PYXS). The simple moving average for the past 20 days is -6.71% for PYXS’s stock, with a 56.97% simple moving average for the past 200 days.
Analysts’ Opinion of PYXS
Many brokerage firms have already submitted their reports for PYXS stocks, with BTIG Research repeating the rating for PYXS by listing it as a “Buy.” The predicted price for PYXS in the upcoming period, according to BTIG Research is $8 based on the research report published on February 09, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see PYXS reach a price target of $12. The rating they have provided for PYXS stocks is “Outperform” according to the report published on January 23rd, 2024.
RBC Capital Mkts gave a rating of “Outperform” to PYXS, setting the target price at $7 in the report published on September 05th of the previous year.
PYXS Trading at -11.45% from the 50-Day Moving Average
After a stumble in the market that brought PYXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.87% of loss for the given period.
Volatility was left at 12.87%, however, over the last 30 days, the volatility rate increased by 9.21%, as shares sank -16.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.66% upper at present.
During the last 5 trading sessions, PYXS fell by -14.04%, which changed the moving average for the period of 200-days by +70.94% in comparison to the 20-day moving average, which settled at $4.81. In addition, Pyxis Oncology Inc saw 151.67% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PYXS starting from Connealy Pamela Ann, who purchase 8,000 shares at the price of $1.87 back on Sep 28 ’23. After this action, Connealy Pamela Ann now owns 818,532 shares of Pyxis Oncology Inc, valued at $14,960 using the latest closing price.
Connealy Pamela Ann, the CFO and COO of Pyxis Oncology Inc, purchase 6,426 shares at $1.85 during a trade that took place back on Sep 27 ’23, which means that Connealy Pamela Ann is holding 810,532 shares at $11,868 based on the most recent closing price.
Stock Fundamentals for PYXS
The total capital return value is set at -0.56. Equity return is now at value -51.51, with -38.32 for asset returns.
Based on Pyxis Oncology Inc (PYXS), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -3.31. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is 48.04.
Currently, EBITDA for the company is -80.2 million with net debt to EBITDA at -0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.84.
Conclusion
In summary, Pyxis Oncology Inc (PYXS) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
